{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=18&state=Virginia", "query": { "state": "Virginia", "city": "Fairfax", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 2553, "total_pages": 256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=19&state=Virginia&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=17&state=Virginia&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T02:36:49.115Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01973049", "title": "UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Asunaprevir", "type": "DRUG" }, { "name": "BMS-791325", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo matching Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 26, "location_summary": "La Jolla, California • San Diego, California • San Francisco, California + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01973049" }, { "nct_id": "NCT03468426", "title": "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-squamous, Non-Small-Cell Lung Cancer", "Neoplasms" ], "interventions": [ { "name": "BI 836880", "type": "DRUG" }, { "name": "Ezabenlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2018-07-05", "completion_date": "2024-09-12", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03468426" }, { "nct_id": "NCT06385080", "title": "A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Amivantamab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 287, "start_date": "2024-04-22", "completion_date": "2033-07-28", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 15, "location_summary": "La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385080" }, { "nct_id": "NCT03859583", "title": "Capsaicin Energy Expenditure and Glucose Metabolism", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Insulin Resistance" ], "interventions": [ { "name": "Capsaicin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Control", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "George Mason University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2018-05-29", "completion_date": "2019-08", "has_results": false, "last_update_posted_date": "2019-03-01", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03859583" }, { "nct_id": "NCT02433873", "title": "Prebiotic Effects of Isomalto-oligosaccharide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Microbiota" ], "interventions": [ { "name": "Isomalto-oligosaccharide", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "George Mason University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 54, "start_date": "2015-04", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02433873" }, { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" }, { "name": "Gemcitabine (1000 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2019-12-10", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT04793659", "title": "Fasudil fOr redUcing elopemeNt and Spatial Disorientation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dementia" ], "interventions": [ { "name": "Oral Fasudil 90 mg/day", "type": "DRUG" }, { "name": "Oral Fasudil 180 mg/day", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Woolsey Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 24, "start_date": "2020-12-15", "completion_date": "2022-02-11", "has_results": false, "last_update_posted_date": "2022-07-11", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 6, "location_summary": "Stamford, Connecticut • Lakeland, Florida • Miami Lakes, Florida + 3 more", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Toms River", "state": "New Jersey" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT04793659" }, { "nct_id": "NCT04488003", "title": "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "BRAF Gene Mutation", "BRAF Gene Alteration", "MEK Mutation", "MEK Alteration", "MAP2K1 Gene Mutation", "MAP2K1 Gene Alteration", "MAP2K2 Gene Mutation", "MAP2K2 Gene Alteration" ], "interventions": [ { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Physician's Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioMed Valley Discoveries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2021-01-07", "completion_date": "2023-05-23", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04488003" }, { "nct_id": "NCT05211895", "title": "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 791, "start_date": "2022-02-18", "completion_date": "2027-09-08", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 32, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05211895" }, { "nct_id": "NCT02271139", "title": "Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-22T02:36:49.115Z", "location_count": 45, "location_summary": "Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more", "locations": [ { "city": "Bimingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02271139" } ] }